The diagnostics company has partnered with Thermo Fisher Scientific to scale the commercialization of its CARDIO inCode-Score® genetic test for predicting and preventing heart disease across the US and Europe.
The healthcare diagnostics company has received approval from New York State for its CARDIO inCode-Score® genetic test, enabling wider commercial adoption in the US market.
The predictive genetics company GENinCode has published a major clinical study in a leading cardiovascular journal, providing validation for its CARDIO inCode-Score® Polygenic Risk Score.
The healthcare diagnostics company has announced a change in shareholding, with Dowgate Group Limited reducing its stake in the business.
The genetic testing firm reported revenue growth but faces headwinds from NHS restructuring and FDA approval delays, leading to lowered full-year expectations despite some positive developments in key markets.
The healthcare company has launched a new surveillance service for women at high risk of ovarian cancer, working with NHS partners.
The healthcare diagnostics company has announced changes to its major shareholders, with Maven Capital Partners UK LLP increasing its stake.
The healthcare company provides a statement regarding recent share price movements, noting no specific reason for the changes.
The healthcare company announces the upcoming release of its interim results and plans for analyst and investor briefings.
The healthcare diagnostics company reports a 15% increase in revenues for the first half of 2025, but also mentions ongoing regulatory and commercial discussions that suggest potential short-term challenges.